This review highlights the up to 7% risk of venous thromboembolism in cancer patients and discusses the underlying pathophysiology and risk factors.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to VTE risk in cancer; leaves open optimal risk-adapted prophylaxis in prospective trials.
A relationship between tumor and thrombosis is well known. This review covers the aspect of incidence and pathophysiology of cancer-related thromboembolism. Cancer patients have an up to 7 % risk of developing venous thrombosis, partly because they are subject to various circumstantial risk factors such as surgical interventions, immobilization or drugs during their illness. On the other hand, tumors frequently generate a prothrombotic state, which may remain without clinical manifestation or result in anticoagulant-resistent venous thromboembolism. Recently discovered thrombosis-generating mechanisms could help to classify patients in categories with high and low thrombotic risk, which will allow tailored prophylactic and therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Hans Stricker (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: